Under construction – not a live service
Sign in
Taking people in AustriaPhase 2

Tests zoledronic acid to aid healing after shoulder tendon surgery

Tests zoledronic acid after surgery to repair torn shoulder tendons in adults.

Plain-language title generated from the registry record
Registry title: Influence Of Zoledronic Acid On Healing After Arthroskopic Repair Of Chronic Rotator Cuff Lesions A Prospective, Randomized, Placebo-Controlled Phase II Trial ZORRO

Key facts

Where
Vienna, AustriaSee the site
Phase
Phase 2

AI summary: who the study is looking for

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for people aged 50 to 70 with a rotator cuff tear confirmed by MRI, who are having arthroscopic shoulder repair. It tests whether zoledronic acid helps the tendon heal.

Age
Between 50 and 70 years.
Sex
All sexes can join.
Disease stage
Rotator cuff tear confirmed by MRI within 6 months before surgery. The tear has a maximum diameter of 3 cm (1.2 in).
Earlier treatment
People cannot have had earlier treatment with anti-osteoporotic drugs (bisphosphonates, denosumab, teriparatide). They must have had no earlier fracture or surgery of the affected shoulder.

Main reasons for not taking part

  • Pregnancy
  • Known allergy to zoledronic acid or its other components
  • Diabetes mellitus (fasting glucose ≥ 126 mg/dl (7 mmol/L), HbA1C ≥ 6.5% (48 mmol/mol))
  • Rupture of more than two tendons, or isolated subscapularis tendon tear
  • Malignant tumor disease

Read by machine on 9 November 2026.

Where in Austria

  • AUVA Trauma Center ViennaVienna, AustriaTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Trial details

Who runs it
AUVA Trauma Center Vienna
Trial code
NCT03584542EU 2024-519082-22-00
Record updated
14 January 2025
Original description
Longitudinal investigation of zoledronic acid on tendon integrity via magnetic resonance imaging at six, twelve, twentyfour and sixty months after arthroscopic repair of chronic rotator cuff lesions. Null hypothesis: Adjuvant intravenous therapy with zoledronic acid does not improve tendon healing after arthroscopic reconstruction of chronic rotator cuff tears compared to a control group without adjuvant therapy with zoledronic acid.Read full original descriptionShow less

Influence Of Zoledronic Acid On Healing After Arthroskopic Repair Of Chronic Rotator Cuff Lesions A Prospective, Randomized, Placebo-Controlled Phase II Trial ZORRO

Longitudinal investigation of zoledronic acid on tendon integrity via magnetic resonance imaging at six, twelve, twentyfour and sixty months after arthroscopic repair of chronic rotator cuff lesions. Null hypothesis: Adjuvant intravenous therapy with zoledronic acid does not improve tendon healing after arthroscopic reconstruction of chronic rotator cuff tears compared to a control group without adjuvant therapy with zoledronic acid.

Inclusion:  Age between 50 and 70 years  Magnetic resonance imaging verified rotator cuff tear (within 6 months prior to surgery)  Rupture size with a maximum diameter of 3 cm  Willingness to participate in the study  Willingness to participate in a unified physiotherapy with use of a shoulder abduction pad for four weeks postoperatively.

Exclusion:  Patients younger than 50 or older than 70 years of age  Pregnancy  Known allergy to zoledronic acid or other components of the medicinal product  Previous fracture of the affected shoulder  Previous surgery of the affected shoulder  Previous or existing bacterial infection of the affected shoulder  Rupture of more than two tendons in the affected shoulder (massive rotator cuff tear)  Isolated subscapularis tendon tear  Presence of glenohumeral osteoarthritis (Hamada type 3 or higher)  Diabetes mellitus (fasting glucose ≥ 126 mg/dl, HbA1C ≥ 6.5%)  Malignant tumor disease  Pathological dental status  Known disease that interferes with bone metabolism  Concomitant diseases that do not permit general anesthesia  Previous therapy with anti-osteoporotic drugs (bisphosphonates, denosumab, teriparatide)  Epilepsy  Claustrophobia  Chronic alcohol abuse  Drug abuse.

ClinicalTrials.gov NCT03584542 · EU CTIS 2024-519082-22-00